Activating transcription factor-5 (ATF5) is highly expressed in malignant glioma and has a key role in promoting cell survival.
A hallmark of cancer is uncontrolled cellular proliferation, which can arise as a result of overexpression of genes promoting cell survival or downregulation of genes inducing cell death 1 . Genes that are highly expressed in cancer cells and are essential for their survival are appealing targets for the development of novel cancer therapeutics 2 .
ATF5 (also known as ATFx) is a member of the ATF/cAMP responsive element-binding (CREB) family of transcription factors, which comprises a large group of basic leucine zipper proteins whose members mediate diverse transcriptional regulatory functions 3 . ATF5 is an antiapoptotic factor that has a key role in promoting survival in a variety of cell types 4 . Increased amounts of ATF5 have been observed in primary brain tumors, and ATF5 expression is particularly high in glioblastoma, an aggressive form of malignant glioma 5 . Previous studies have shown that interference with ATF5 function results in glioma cell death in primary tumors but does not affect normal cells surrounding the tumor 6 . The high level of ATF5 in brain tumors, coupled with the absence of ATF5 expression in mature neurons, suggests that ATF5 may be an attractive therapeutic target for the treatment of malignant glioma.
The upstream regulators of ATF5 expression and the downstream effectors that mediate the antiapoptotic effects of ATF5 remain to be determined. Here we describe a unique genome-wide RNAi negativeselection screening strategy that has enabled us to elucidate a pathway by which ATF5 is expressed and prevents apoptosis. Our results reveal an essential survival pathway in malignant glioma, the inhibition of which has therapeutic implications.
RESULTS

A signaling pathway required for ATF5 expression
To identify factors that regulate ATF5 transcription, we performed a genome-wide shRNA screen to isolate genes that, when knocked down, greatly reduce ATF5 expression. Because loss of ATF5 function would induce apoptosis 5, 7 and prevent the subsequent identification of candidate shRNAs, we developed a negative-selection strategy (Fig. 1a) based on the ability of diphtheria toxin to kill cells expressing the diphtheria toxin receptor (DTR). Mouse cells lack a functional DTR and are resistant to diphtheria toxin 8 . We generated a mouse malignant glioma GL261 cell line stably expressing the human DTR driven by the mouse Atf5 promoter (pATF5-DTR). To prevent cell death due to loss of endogenous ATF5, we also engineered the cell line to stably express ATF5 driven by the constitutive cytomegalovirus (CMV) promoter (pCMV-ATF5). The resulting cell line was termed GL261-pATF5-DTR-pCMV-ATF5; as expected, these cells were efficiently killed by addition of diphtheria toxin (Supplementary Fig. 1a) .
A mouse shRNA library comprising ~62,400 shRNAs directed against ~28,000 genes 9 was divided into ten pools, which were a r t i c l e s 6 7 2 VOLUME 16 | NUMBER 6 | JUNE 2010 nature medicine packaged into retrovirus particles and used to stably transduce GL261-pATF5-DTR-pCMV-ATF5 cells. We treated cells with diphtheria toxin and isolated diphtheria toxin-resistant clones. We identified positive shRNAs by sequence analysis and tested their ability to inhibit endogenous Atf5 gene expression ( Supplementary Fig. 1b ).
With this approach, we identified and validated 12 genes that are required for endogenous Atf5 expression in mouse malignant glioma GL261 cells ( Supplementary Table 1 ). We elected to focus on three factors: fibroblast growth factor receptor (FGFR) substrate-2 (FRS2), p21 protein-activated kinase-1 (PAK1) and CREB3L2. To our knowledge, none of these factors were previously known to regulate each other or ATF5. FRS2 is a docking protein that binds receptor tyrosine kinases, such as FGFR or epidermal growth factor receptor (EGFR), and leads to activation of RAS signaling 10 ; notably, the RAS signaling pathway is frequently activated in malignant gliomas, owing to aberrant expression of receptor tyrosine kinases including FGFR and EGFR 11 . PAK1 is a kinase that functions as a positive regulator of mitogen-activated protein kinase (MAPK) signaling 10, 12 . CREB3L2 is a member of the CREB family of transcription factors, which bind to DNA sequences known as cAMP responsive elements (CRE) 13 . CREB3L2 is homologous to CREB3, whose activity and expression is regulated by MAPK signaling 14 . We therefore hypothesized that FRS2, PAK1 and CREB3L2 comprise a signaling pathway that culminates in increased Atf5 expression. To test this hypothesis, we first confirmed that FRS2, PAK1 and CREB3L2 were required for Atf5 expression. We designed siRNAs against FRS2, PAK1 and CREB3L2 whose sequences were unrelated to the shRNAs isolated in the primary screen; siRNA-mediated knockdown of FRS2, PAK1 or CREB3L2 ( Supplementary Fig. 1c ) resulted in decreased Atf5 expression ( Fig. 1b) , confirming that these three factors are upstream activators of Atf5 transcription.
To determine whether Atf5 expression is modulated by signaling through FGFR, EGFR or RAS, we treated GL261 cells with an inhibitor of FGFR (PD173074) 15 , EGFR (CL-387,785) 16 or RAS (manumycin A) 17 and monitored Atf5 expression by quantitative real-time RT-PCR (qRT-PCR) and immunoblot analysis. All three inhibitors reduced Atf5 expression at both the mRNA and the protein levels ( Supplementary Fig. 1d,e ).
To determine whether downstream signaling pathways of RAS, such as the MAPK and phosphoinositide 3-kinase (PI3K) pathways, are required for Atf5 expression, we treated GL261 cells with the RAF kinase inhibitor sorafenib 18 Fig. 1c) .
We next investigated whether CREB3L2 directly regulates Atf5 expression. Bioinformatic analysis of the Atf5 promoter revealed a consensus CRE motif at −632 to −639 bp upstream of the transcription start site ( Fig. 1d) . Chromatin immunoprecipitation (ChIP) analysis demonstrated that CREB3L2 directly binds a region of the Atf5 promoter containing a consensus CRE motif, but not a region further upstream ( Fig. 1d) . Moreover, binding of CREB3L2 to the Atf5 promoter was inhibited by sorafenib ( Fig. 1d) . To confirm the functional role of CREB3L2 in Atf5 transcription, we made a reporter construct in which ~4 kb of the Atf5 promoter was fused upstream of the luciferase gene. The wild-type Atf5 promoter, but not a derivative in which several nucleotides in the CRE motif were mutated, substantially stimulated luciferase production ( Fig. 1e) . Lastly, we found that endogenous Creb3l2 expression was substantially lowered by treatment of GL261 cells with an siRNA against FRS2 or PAK1 or an inhibitor of MAPK or PI3K ( Supplementary Fig. 1f-h) . Taken together, these results indicate that FRS2, PAK1 and CREB3L2 are components of RAS-MAPK-and PI3K-directed pathways that regulate ATF5 expression. Next, we performed several experiments to confirm that the ATF5mediated survival pathway is required for viability of malignant glioma cells. First, shRNA-mediated knockdown of FRS2, PAK1 or CREB3L2 induced apoptosis in GL261 cells, as evidenced by increased caspase-3 and caspase-7 activity ( Fig. 1f) . Notably, apoptosis could be blocked by ectopic expression of ATF5 ( Fig. 1f) . Similarly, the RAF inhibitor sorafenib ( Fig. 1g ) and inhibitors of FGFR, EGFR, RAS and PI3K ( Supplementary Fig. 1i ) induced apoptosis in GL261 cells but not in cells ectopically expressing ATF5. By contrast, JNK inhibitor I and SB203580, which did not affect Atf5 expression (see Fig. 1c ), failed to induce apoptosis in GL261 cells ( Fig. 1g) .
Lastly, we investigated whether the ATF5-mediated survival pathway is required for malignant glioma cell proliferation in a mouse syngenic model. We injected GL261 cells stably expressing ATF5 or empty vector into the flanks of mice and subsequently administered vehicle or sorafenib by gavage. As expected, control mice injected with GL261 cells developed tumors, but we did not detect tumors in GL261-injected mice treated with sorafenib ( Fig. 1h) . Notably, ectopic expression of ATF5 in GL261 cells substantially reduced sensitivity to sorafenib (Fig. 1h) . Taken together, these data indicate that RAS-MAPK-or PI3K-mediated activation of ATF5 expression is essential for survival of malignant glioma cells both in culture and in mouse xenografts.
ATF5 promotes survival through upregulation of MCL1
Previous studies have shown that sorafenib can induce apoptosis by decreasing the level of MCL1, an antiapoptotic B cell leukemia-2 (BCL2) family member 24 , which we confirmed also occurred in GL261 cells ( Fig. 2a) . This observation raised the possibility that ATF5 may prevent apoptosis by upregulating MCL1 expression; we therefore performed a series of experiments to investigate this possibility. Knockdown of ATF5 by an siRNA decreased expression of MCL1 but had no effect on the expression of several other antiapoptotic BCL2 proteins including BCL2, BCL2-like-1 (BCL2L1, also called BCL-X L ) and baculoviral IAP repeat-containing-3 (BIRC3, also called cIAP2) ( Fig. 2b) .
We next sought to determine whether ATF5 regulates Mcl1 transcription. Knockdown of ATF5 decreased Mcl1 mRNA levels ( Fig. 2c ) and, conversely, overexpression of ATF5 increased Mcl1 mRNA levels ( Supplementary Fig. 2 ). To determine whether ATF5 directly binds the Mcl1 promoter, we performed ChIP experiments with a series of primer pairs that spanned the Mcl1 promoter. ATF5 binding was enriched at two regions of the Mcl1 promoter corresponding to −1531 to −1358 bp and −853 to −718 bp upstream of the transcription start site ( Fig. 2d) . Notably, binding of ATF5 to both Mcl1 promoter regions was inhibited by sorafenib ( Fig. 2d) .
We next asked whether MCL1 is required for ATF5-mediated survival by monitoring GL261 cells stably expressing MCL1 for apoptosis after siRNA-mediated knockdown of ATF5. ATF5 knockdown induced apoptosis in control GL261 cells, as evidenced by the production of cleaved caspase-3 ( Fig. 2e) . Notably, apoptosis was substantially inhibited by ectopic expression of MCL1 ( Fig. 2e) . Collectively, these results indicate that MCL1 is a downstream effector of an ATF5mediated survival pathway ( Fig. 2f) .
We next asked whether the ATF5-mediated survival pathway is generally active in human cancer cell lines. A search of the Oncomine cancer profiling database 25, 26 revealed that ATF5 expression is elevated in a wide range of tumors relative to normal tissue ( Supplementary  Table 2 ). Moreover, siRNA-mediated knockdown of ATF5 in several diverse human cancer cell lines, U87MG (glioblastoma), DU145 (prostate), UACC62 (melanoma), A549 (lung) and OVCAR3 (ovary) resulted in inhibition of MCL1 expression and induction of apoptosis ( Fig. 2g) . These results suggest that the ATF5 pathway mediates cell survival in malignant glioma and diverse human cancer cell lines. First, as mentioned above, ATF5 is highly expressed in human glioblastoma cells but not in normal brain tissues 5 . Second, the FRS2 gene is amplified in a subset of malignant gliomas 27 . Finally, previous studies have shown that the activities of PAK1 and ERK correlate with prognosis in glioblastoma 28, 29 . A search of the Oncomine database revealed that, like ATF5, FRS2, CREB3L2 and MCL1 are upregulated in human glioblastoma compared to normal brain samples ( Supplementary Fig. 3a) . Moreover, genome-wide analysis of focal copy number in human glioblastoma 30 also indicates that components of the ATF5-mediated survival pathway are amplified in the disease (Supplementary Fig. 3b) .
To confirm and extend these results, we performed immunohistochemistry on a panel of four normal human brain samples and 38 glioblastomas; representative examples are shown in Figure 3a , and the results summarized in Supplementary Figure 3c . Positive staining for phosphorylated ERK (pERK), ATF5, CREB3L2 or MCL1 was found in 50-74% of malignant gliomas and, notably, 42% of malignant gliomas stained positively for all four proteins. By contrast, none of the four proteins were detected by immunohistochemical analysis in normal brain. Statistical analysis revealed a correlation in malignant gliomas between pERK and either CREB3L2 or ATF5 and between CREB3L2 and either ATF5 or MCL1 ( Supplementary  Fig. 3d) . By contrast, we did not observe a significant correlation between MCL1 and either pERK or ATF5, suggesting that MCL1 expression may be regulated by alternative pathways in malignant glioma. This conclusion is consistent with previous studies demonstrating that MCL1 expression can be regulated by both transcriptional and post-transcriptional mechanisms 31, 32 .
To determine whether there is a correlation between ATF5 expression and prognosis of individuals with glioblastoma, we analyzed the clinical history of 23 individuals with malignant glioma and performed Kaplan-Meier analysis. This analysis revealed that individuals with ATF5-positive glioblastomas had substantially shorter survival times than those with ATF5-negative glioblastomas (Fig. 3b) . As expected from previous studies 29 , pERK showed a similar correlation with clinical outcome (Fig. 3b) . Thus, ATF5 expression is a marker of clinical outcome in individuals with malignant glioma.
Role of the ATF5 pathway in human malignant glioma cells
Malignant glioma is thought to arise from self-renewing progenitors termed glioma stem cells (GSCs) 33 , which are highly resistant to chemo-and radiotherapies 34 . To test whether components of the ATF5-mediated survival pathway are overexpressed in GSCs, we isolated GSCs from either a human malignant glioma primary cell line (GS9-6) or a human glioblastoma cell line (D456MG) maintained as a subcutaneous xenograft and analyzed expression of ATF5-mediated survival pathway components by immunoblot and qRT-PCR analyses. As a control, we also monitored the expression of ATF5 pathway components in GS9-6 and D456MG GSCs after induction of differentiation by treatment with serum. As expected, serum treatment induced differentiation of GS9-6 GSCs, as evidenced by upregulation of glial fibrillary acidic protein (GFAP), an astrocytic marker, and downregulation of nestin, a stem cell marker (Fig. 4a) . Upon differentiation, CREB3L2, ATF5 and MCL1 abundance decreased, indicating that these proteins are enriched in undifferentiated GS9-6
GSCs. Furthermore, qRT-PCR analysis verified that expression of CREB3L2, ATF5 and MCL1 decreased after differentiation of GS9-6 and D456MG GSCs (Fig. 4b) .
To determine whether, as in malignant glioma cells, the ATF5mediated survival pathway was regulated by MAPK signaling in GSCs, we treated GS9-6 GSCs with sorafenib and assessed expression of CREB3L2, ATF5 and MCL1 by immunoblotting ( Fig. 4c) and qRT-PCR analysis (Fig. 4d) . The results show that sorafenib reduced expression of CREB3L2, ATF5 and MCL1 at both the protein and mRNA levels (Fig. 4c,d) . Furthermore, sorafenib treatment induced apoptosis in GS9-6 GSCs, as evidenced by elevated amounts of cleaved caspase-3 (Fig. 4c) . Consistent with this result, sorafenib treatment resulted in decreased cell viability of both undifferentiated and differentiated GS9-6 GSCs (Fig. 4e) . Thus, the ATF5-mediated survival pathway we identified in mouse malignant glioma is also essential for survival of human malignant glioma cells.
Sorafenib suppresses growth of malignant glioma in mice
To test whether sorafenib could suppress development of brain tumors, we used an established orthotopic mouse model of human malignant glioma 35 . In brief, we injected GSCs intracranially into mice, treated them in the presence or absence of sorafenib and monitored tumor development by magnetic resonance imaging (MRI) (representative examples are shown in Fig. 5a ). All of the mice treated with vehicle harbored a tumor >5 mm 3 , and 50% had a tumor >25 mm 3 (Fig. 5b) . By contrast, only 60% of the mice treated with sorafenib had a tumor >5 mm 3 , and none had a tumor >25 mm 3 (Fig. 5b) . Immunohistochemical staining of tumor sections for cleaved caspase-3 confirmed that sorafenib treatment reduced tumor growth by inducing apoptosis (Fig. 5c,d) . Taken together, these data demonstrate that inhibition of MAPK signaling suppresses development of malignant glioma in a mouse model.
Finally, we investigated whether sorafenib could synergize with temozolomide, a chemotherapeutic agent used to treat glioblastomas 36 , to inhibit tumor cell growth. We found that sorafenib and temozolomide synergistically decreased the viability of U87MG human glioblastoma cells (Fig. 6a) , which express high levels of ATF5 and CREB3L2 (Supplementary Fig. 4a ), but not of SF295 human glioblastoma cells (Supplementary Fig. 4b ), which express low levels of ATF5 and CREB3L2 (Supplementary Fig. 4a) . We also observed a synergistic effect on tumor growth in U87MG mouse subcutaneous xenografts (Fig. 6b) . Taken together, these results indicate that sorafenib can sensitize glioblastoma cells to temozolomide and further suggest that such sensitization selectively occurs in cells expressing high levels of ATF5.
DISCUSSION
ATF5 is expressed in high levels in malignant glioma but not in mature neurons or astrocytes 6 . Moreover, interference with ATF5 function results in glioma cell death in primary tumors without affecting normal cells surrounding the tumor 6 . These findings suggest that ATF5 is an attractive target for the development of therapeutics for malignant glioma 4 . However, ATF5 is a transcription factor, a class of molecules for which the development of small-molecule drugs has proven challenging 37 . An alternative strategy to targeting ATF5 directly is to interfere with upstream regulators of ATF5 expression or downstream effectors through which ATF5 promotes survival.
In this report, we have described a new negative-selection strategy using genome-wide RNAi screening to elucidate RAS-MAPK-and Tumor formation was monitored by MRI (left); the position of the tumor is indicated by the arrowhead. Brain sections were stained with H&E (middle) or an antibody to GFAP (right) to verify the glial origin of the tumor. Expression of CREB3L2, ATF5 and MCL1 in these sections is shown in Supplementary Figure 5 PI3K-directed signaling pathways by which ATF5 is expressed and promotes survival of malignant glioma cells. The genome-wide RNAi screening strategy we have developed can be generally applied to identify other survival pathways in cancer cells. Our results enable us to propose a model for an essential survival pathway in malignant glioma and other solid tumors (Fig. 2f ). An FRS2-or PAK1-activated RAS-MAPK signaling cascade upregulates CREB3L2, which directly binds the ATF5 promoter, resulting in ATF5 transcription. FRS2 may also activate ATF5 transcription through PI3K signaling. ATF5 then stimulates MCL1 transcription by binding its promoter, resulting in increased expression of the antiapoptotic protein MCL1, which promotes cell survival. Our results do not rule out the possibility that other ATF5 targets, which remain to be identified, may also contribute to the inhibition of apoptosis.
We have shown that pharmacological inhibition of this pathway substantially decreases ATF5 abundance and blocks proliferation of malignant glioma cells both in cell culture and in mouse tumor models. Our experiments were carried out with the well characterized RAF inhibitor sorafenib at concentrations in cultured cells and at doses in mice [38] [39] [40] that approximate the levels of sorafenib achieved in subjects treated with the drug [41] [42] [43] [44] . Moreover, we have found that in the presence of temozolomide, the drug most commonly used to treat malignant glioma, the concentration of sorafenib required for growth inhibition is markedly reduced. Thus, when combined with temozolomide, the sorafenib concentration obtainable in patients may be well above that required for an effective response. Finally, although our sorafenib results clearly demonstrate that the prosurvival pathway we have identified can be pharmacologically inhibited, it is likely that more recently developed RAF inhibitors 45 , and inhibitors of other components of this ATF5-mediated survival pathway, such as MEK, may be even more efficacious. 
METHODS
Methods
ONLINE METHODS
RNA intereference. For pATF5-DTR, we amplified 4,117 bp of the mouse Atf5 promoter from a bacterial artificial chromosome clone and cloned it into pEF4/Myc-His B (Invitrogen), then amplified the gene encoding human DTR from mCD11C-DTR-EGFP 46 and cloned it downstream of the Atf5 promoter. For pCMV-ATF5, we amplified ATF5 cDNA from pCMV-SPORT6-ATF5 (Open Biosystems) and cloned it into p3XFlag-myc-CMV-26 (Sigma). We transduced GL261 cells stably expressing pATF5-DTR and pCMV-ATF5 with retroviral pools of a mouse shRNA mir library (Open Biosystems), as previously described 47 . We incubated cells with 100 pM diphtheria toxin for 7 d and cultured surviving cells in medium without diphtheria toxin for 2 weeks. To validate candidates, we transiently transfected GL261 cells with a single shRNA, assessed expression of endogenous Atf5 by RT-PCR (with primers listed in Supplementary Table 3 ) and quantified with Image J software (NIH). For RNAi, we transiently transfected GL261 cells (5 × 10 5 ) with an siRNA or shRNA ( Supplementary Table 3 ) using Effectene (QIAGEN).
Quantitative reverse transcription PCR. Quantitative RT-PCR was performed as previously described 47 with the primers listed in Supplementary Table 3 .
Chromatin immunoprecipitation. ChIP assays were performed as previously described 48 with the antibodies listed in Supplementary Table 3 . Immunoprecipitated DNA was amplified by real-time PCR (primers listed in Supplementary Table 3 ).
Luciferase reporter assay. We cloned the mouse Atf5 promoter into pGL4.14 (luc2/Hygro; Promega) and mutated the CRE element into a NotI site. We transfected this plasmid and pGL4.73 (hRluc/SV40; Promega) into GL261 cells and assessed luciferase activity 48 h later with the Dual-Luciferase Reporter Assay System (Promega). Relative luciferase activity was calculated and normalized to empty vector.
Apoptosis assays. We measured apoptosis with a Caspase-Glo 3/7 Assay (Promega). To eliminate background caspase activity, caspase-3/7 activity was normalized to cell number (obtained from an MTT assay) and then to the activity obtained with the control shRNA.
Preparation of glioma stem cells.
For GS9-6 cells, a freshly-resected tumor, never treated with radio-or chemotherapy, was dispersed with trypsin and placed into neurosphere culture in DMEM/F12 medium supplemented with B27 (Invitrogen), 20 ng ml −1 fibroblast growth factor (PeproTech) and 20 ng ml −1 epidermal growth factor (PeproTech). For passaging, we dispersed neurospheres with a basic solution 49 and maintained them in the medium described above. D456MG GSCs were prepared as previously described 34 .
Mouse tumorigenesis assays. For the syngenic model, we injected 1 × 10 6 GL261 cells subcutaneously into the flank of C57/BL6 mice (Taconic), aged 8 weeks. Tumor volume was calculated ((length × width 2 ) × (π / 6)). We fed mice daily with sorafenib (60 mg per kg body weight) or vehicle (cremphor:ethanol: water 12.5%:12.5%:75%) through gavage starting at 4 d. Mice were killed 31 d after injection. For the orthotopic model, we implanted 5 × 10 5 GS9-6 cells stereotaxically in the right frontal lobe (from bregma, anteroposterior, 2 mm; mediolateral, 2 mm; ventral (from dura), 2 mm) of NIH-bg-nu-xidBR mice (Charles River Laboratories), as previously described 35 . We administered sorafenib (100 mg per kg body weight) or vehicle daily through gavage starting at 7 d. Tumor growth was monitored at the UMMS Image Core of Advanced MRI with a Philips DICOM Viewer R2.4, and tumor volume was calculated (length × width × depth). After 81 d, mice were imaged and killed, and their brains were sectioned and fixed in formalin. We performed all mouse experiments in accordance with the Institutional Animal Care and Use Committee guidelines.
Temozolomide experiments. We treated U87MG or SF295 cells with sorafenib, temozolomide (Sigma) or both for 4 d and monitored cell viability by MTT assay. For the xenografts, we injected 5 × 10 6 U87MG cells subcutaneously into the flank of nude mice (Taconic), aged 6-8 weeks. Starting at 15 d, we fed mice daily with sorafenib (20 mg per kg body weight), temozolomide (7.5 mg kg −1 ) or a combination of both through gavage, then treated them with sorafenib for another 10 d. Mice were killed 30 d after injection. Tumor dimensions were measured every 3 d, and tumor volume was calculated.
Statistical analyses.
We performed all analyses in R 2.9.0 50 . We performed Welch's two-sample t test 51 on log-transformed qPCR data (Figs. 1b,c,e, 2a,c  and 4d ) and log-transformed relative caspase activity data ( Fig. 1f,g) . We performed repeated-measures analysis of variance on log-transformed tumor volume ( Figs. 1h and 6b) . In addition, we performed a list of predetermined contrasts to test whether sorafenib treatment decreased tumor volume in the absence or presence of ATF5 and whether combined sorafenib and temozolomide treatment decreased tumor volume significantly compared with sorafenib or temozolomide treatment alone. We applied analysis of variance to the ranktransformed cell viability data to test the effect of serum, sorafenib and the interaction of serum and sorafenib ( Fig. 4e) and of temozolomide, sorafenib and the interaction of temozolomide and sorafenib (Fig. 6a) . A linear mixed-effects model was fit to the log-transformed tumor volumes ( Fig. 5b) or to the number of apoptotic cells (Fig. 5d) , with treatment as a fixed effect and experiment day as a random effect to determine whether the tumor size differs between treatments using R package nlme_3.1-90.
